Medical Supplies

Uusikatu 49 A 1
90120 Oulu
Finland

Phone: (+358-10)4005090
Fax: (+358-10)4005011
http://www.mediracer.com
info@mediracer.com

Company Figures
Number of employees 1-19
Sales volume < 1 Mio US $
Export content max. 50%
Year of foundation 2002
Area of business Electronical Equipment / Medical Technology

Diagnostics

Company Profile

About Us...
Mediracer Ltd is a medical technology company based in Oulu, Finland, that specialises in the development of Point of Care (POC) diagnostic testing equipment for ailments of the peripheral nervous system.

Developed in collaboration with clinical neurophysiology specialists, the Mediracer® CTS Test Device is a completely new type of test device for diagnosing carpal tunnel syndrome (CTS). Clinical tests have verified that the Test Device gives sensitivity of >94% and specificity of >98%. The product received CE approval in 2005 and is now on sale throughout the EU area as well as in those countries of the Middle East and Asia where CE approval is a sufficient requirement.

Mediracer Ltd’s POC product family will be supplemented over the next few years with numerous new products. The Mediracer product and service concept makes expert services easily available to individual healthcare units throughout the world.

The Mediracer® brandname is owned and registered by Mediracer Ltd in the EU and the USA.

Product Information
01.01.01.06 Microscopes

01.01.01.08 Electromedical instruments and instruments for neurological diagnosis
The Mediracer® CTS Test Device 18.10.2007

Carpal

tunnel syndrome (“CTS”) is

probably the most common upper

extremity problem with 3-5% prevalence

in the adult population. In addition about 15%

of the population suffer from occasional CTS

symptoms; numbness, tingling, and pain in the hand.

Undiagnosed and untreated CTS may have longlasting

ill-effects. Whether the treatment is nonsurgical

or surgical, an early diagnosis is crucial.

With the Mediracer® CTS Test Device you

will be able to confi rm CTS fast, costeffectively,

and reliably; sensitivity

94% and specifi city 98%.

01.01.01.08.02 Evoked potentials, somatosensory, visual, acoustic